– March 1, 2013
March 1, 2013
View Issues
Phase 1 Trial of Intraventricular Rituximab and Methotrexate in Heavily Pretreated Patients with Recurrent CNS Lymphoma
This Phase 1 clinical trial evaluated the safety and pharmacokinetics of intraventricular immune-chemotherapy with twice weekly rituximab (10 mg and 25 mg) and methotrexate in 14 patients with recurrent central nervous system lymphoma (primary or secondary).Management of Early-Stage Common Bile Duct Cancer
A 52-year-old female presented with right flank pain, elevated bilirubin, and mild jaundice to her primary care physician. Endoscopic retrograde cholangiopancreatography demonstrated a common bile duct stricture just above the pancreatic head with a suggestion of neoplasia.Post RT Adjuvant Cetuximab for Locally Advanced Oropharyngeal Cancer
In a randomized, Phase 2 trial, weekly maintenance cetuximab for 12 weeks after concomitant definitive radiation therapy/cetuximab induction was associated with better disease-free survival at 1 year.Parenteral Iron for Cancer-Associated Anemia
In an observational study conducted in Germany of more than 600 anemic cancer patients receiving parenteral iron (ferric carboxymaltose), hemoglobin levels were shown to rise significantly.‘Off-target’ Effects? The Role of Statins in Cancer Biology
Statin use among cancer patients with diverse malignancies is associated with reduced cancer-related mortality.Pharmacology Watch: Aspirin Use and Age-Related Macular Degeneration
Aspirin use and AMD risk; using NSAIDs and antihypertensive agents; and FDA actions.Clinical Briefs in Primary Care Supplement